Neuphoria Therapeutics Inc. Deferred Federal Income Tax Expense (Benefit)
Neuphoria Therapeutics Inc. (NEUP) reported Deferred Federal Income Tax Expense (Benefit) of -$1.53 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-09-18
- Neuphoria Therapeutics Inc. deferred federal income tax expense (benefit) for fiscal 2026 was -$1.53M.
- Neuphoria Therapeutics Inc. deferred federal income tax expense (benefit) for fiscal 2025 was -$532.00K.
- Neuphoria Therapeutics Inc. deferred federal income tax expense (benefit) for fiscal 2024 was -$118.95K.
- Neuphoria Therapeutics Inc. deferred federal income tax expense (benefit) for fiscal 2023 was -$124.58K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2026-06-30 | -$1.53M 10-K · filed 2026-09-18 |
| 2025-06-30 | -$532.00K 10-K · filed 2026-09-18 |
| 2024-06-30 | -$118.95K 10-K · filed 2025-09-29 |
| 2023-06-30 | -$124.58K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |